SAA1 and esophageal cancer: As an essential member of the SAA family, SAA1 has been reported as a risk and prognosis biomarker in tumorigenesis, metastasis, and therapy and is highly expressed in gastric cancer, lung cancer, prostate cancer, endometrial cancer, esophagus cancer, and melanoma, which presented poor prognosis in patients (23–28).